
RadOnc @YashodaHospital via @UTMDAnderson, @RadOncTMC @CanGenetics_TMC and OsmaniaMed | Organ preservation & Radiobiology | opinions my own |
Hyderabad, India
Joined November 2018
- Tweets1.2K
- Following749
- Followers909
- Likes10.1K
Tejaswi Kanala MD retweeted
They're calling it the greatest opening paragraph of any recent oncology article
Tejaswi Kanala MD retweeted
You can mock Indian doctors all you want, but that won’t make your product scientifically validated.
Nobody is asking why you left a $35 billion company. Nobody is questioning your ambition or vision for humanity.
We are asking one simple question: Where is the independent scientific evidence supporting your health claims?
Doctors spend years learning to distinguish genuine medical breakthroughs from impressive marketing.
Questioning unvalidated claims isn’t being “holier-than-thou.”
And if doctors asking for evidence irritates you this much, perhaps the problem isn’t the doctors.
Science welcomes scrutiny.
Marketing fears it.
A lot of you have pinged me to ask - why are you doing Temple? Why did you leave a ~$35b company you founded 18 years ago to chase a niche health wearable? This doesn’t sound rational.
Why did I leave Eternal? What are we building at Temple? What’s our vision statement? What do we have in store for humanity?
I am going to tell you in 4 hours from now (drafting the note as we speak). Stay tuned.
PS – holier-than-thou Indian doctors can skip this lol.
Tejaswi Kanala MD retweeted
MDT was associated with better disease control. It's retrospective, so it needs prospective testing.
This one is close to me. It's where I learnt stats by doing it, from univariable and multivariable analysis to sensitivity analyses. The methods are the part I'm proudest of.
What a delight it was sharing a ride with Dr. Jayanand Sudhir, an authority on management of Moyamoya disease. We spoke about its rising incidence in India, AVMs, endovascular coiling, and… radiation therapy.
It’s nice to step outside the world of oncology once in a while.
16
964
Tejaswi Kanala MD retweeted
Now in @JAMAOnc:
We report 5y outcomes post 30 Gy elective RT (total 70 Gy CCRT) for 276 pts w/ HPV-related OPC #hncsm at @MSKCancerCenter #radonc
LRC 97.0%
OS 90.8%
PFS 85.9%
DMFS 91.2%
@imrtlee @xrtGenomics @seanmmcbride @CJTsaiMDPhD @EChrisDee
👉 shorturl.at/liqpP
Tejaswi Kanala MD retweeted
We seek an expert who can advice us on this aspect of cancer care (sexual intimacy while being a patient with cancer). #HopeSupport
We join the oncology community in mourning the passing of Dr. Rachna T. Shroff, a renowned GI cancers expert and a dedicated ASCO volunteer. We are humbled by her dedication and strive to honor her legacy of commitment and altruism.
Read more: bit.ly/4e7jBKu
Tejaswi Kanala MD retweeted
This trial randomizes mCRC pts w oligoprogressive dz to Local therapy plus Same-line systemic Tx versus Next-line systemic Tx. @ChadTangMD and I excited to share results from the EXTEND-OP histology-specific cohorts soon! @michael_overman @ryanhuey @DanielHaldarMD @MadhuEluri 2/2
Tejaswi Kanala MD retweeted
Audi Hoang and Dr. Tejaswi Kanala presented studies that both examined the role of proton craniospinal irradiation in leptomeningeal disease at #ASTRO26. @TSKanala #EndCancer
Tejaswi Kanala MD retweeted
Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial
thelancet.com/journals/lanep…
Tejaswi Kanala MD retweeted
Anthropic is hiring a Research Scientist (post PhD) with biology & computational skills in its life sciences division for a $300-$320 K salary (2-3 times what a starting Assistant Professor would make in academia, after a serious postdoctoral fellowship).
Brave new world!
Tejaswi Kanala MD retweeted
A tiny linear accelerator that’s become my favorite desk companion.
Curious—would you have one on your desk? 👀
#RadiationOncology #Radiotherapy #MedEd #MedicalPhysics
Thanks to @eugenekoay , @ebludmir , Dr Randa Tao, Dr Juan Valle @curecc and GI RadOncs of ICRN for their time, input, and the opportunity to present this work. #CCAHope
1
3
171
Thank you, Dr @StephenLChan1, president, @ILCAnews, for your input on our work. It was a pleasure listening to your talk on local therapies in liver cancer at #ESMOGI26
2
108
Tejaswi Kanala MD retweeted
Increased toxicity (& cost) w TACE/systemic combo, so why not give drug(s) at progression? No demonstrated OS benefit yet w upfront.
Also given TACE lower local control, PFS benefit (3-5 mo) from systemic addition might partly reflect compensation for local failures. @OncoAlert
EMERALD-3 may redefine treatment for embolization-eligible HCC.
Adding STRIDE + TACE significantly improved PFS, ORR and DoR versus TACE alone, with a manageable safety profile.
Early OS trend is encouraging, although longer follow-up is awaited.
Will this change the practice? 🤔 @GIcancerDoc
@GABOUALFA @NiuSanford
#ESMOGI26 @myESMO @OncoAlert




























